DDR on DTC: QuillivantXR

Share this article:
Deborah Dick-Rath
Deborah Dick-Rath

Sometimes the regulatory environment can be more than challenging for a brand, it can be debilitating. I was recently reading People magazine and noticed a detail aid in there masquerading as a DTC ad for Pfizer's QuillivantXR. How times have changed. Pfizer, once a mighty powerhouse of DTC innovation blasting groundbreaking campaigns for Viagra, Lipitor, Zyrtec and Zoloft, has been relegated (or should I say regulated?)  to running this “ad-like object” for its new ADHD brand.

 

Unfortunately, Quillivant is in a scheduled category loaded with warnings and PR issues, so we have to admire Pfizer and the Quillivant team for putting their brand out there at all—and not just in a below-radar, in-office publication, but in one of the biggest magazines guaranteed to reach their target audience of moms. That's the good news. The bad news is that the creative was limited to a wall of ISI with a bullet list of product features. There is no emotional insight or context to resonate with the target.

A box in the lower right corner contains a tiny call-to-action and the URL. The website mirrors the print ad imagery and you can register for the typical CRM and co-pay opportunities. Like a detail aid, we have a logo shot on the ad—in this case, a liquid “Q” to show that the product comes in liquid form. But unlike a detail aid, we don't get a human being to tell us the story of the brand—and sadly, this ad alone doesn't either.


Deborah Dick-Rath is the president of Epic Proportions, a healthcare communications consultancy. She can be reached at deborahdrath@optonline.net
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?